931075-55-7 Usage
Description
6-(chloromethyl)-1-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one is a heterocyclic organic compound characterized by a complex molecular structure that features a pyrazolo and pyrimidin ring system. It is distinguished by the presence of a chloromethyl and a methyl group, which contribute to its unique reactivity and potential applications in pharmaceutical research and development.
Uses
Used in Pharmaceutical Research and Development:
6-(chloromethyl)-1-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one is utilized as a key intermediate in the synthesis of new drugs and pharmaceuticals. Its unique structure and reactivity make it a promising candidate for the development of innovative therapeutic agents.
Used in Drug Synthesis:
In the pharmaceutical industry, 6-(chloromethyl)-1-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one serves as a building block for the creation of novel compounds with potential medicinal properties. Its versatility in chemical reactions allows for the exploration of various therapeutic avenues.
Used in the Development of Therapeutic Agents:
Due to its potential biological activity, 6-(chloromethyl)-1-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one may be employed in the development of new treatments for various diseases and conditions. Its integration into drug discovery pipelines can lead to the identification of effective and targeted therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 931075-55-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,1,0,7 and 5 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 931075-55:
(8*9)+(7*3)+(6*1)+(5*0)+(4*7)+(3*5)+(2*5)+(1*5)=157
157 % 10 = 7
So 931075-55-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H7ClN4O/c1-12-6-4(3-9-12)7(13)11-5(2-8)10-6/h3H,2H2,1H3,(H,10,11,13)
931075-55-7Relevant articles and documents
COMBINATION THERAPY FOR TREATING MPS1
-
Paragraph 0749-0752, (2021/08/14)
The application is directed to compounds of formula (I) and their salts and solvates, wherein B, R1, R2, R3, R3', R4, R4', and R5 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., MPS1, optionally in combination with α-L-iduronidase or an analog or variant thereof, e.g., laronidase.
